Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Target Price
The average target price of BOLT is 21 and suggests 449% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell